Phase III trials comparing AZD9291 (FLAURA, NCT02296125) and CO-1686 (TIGER 1, NCT02186301) with gefitinib or erlotinib in treatment-naïve patients with EGFR-mutation positive NSCLC are ongoing and recruiting. This evidence concerns the gene EGFR and non-small cell lung carcinoma.